Korea FilingsFull brief — $39

ORIENTBIO Inc.

(주)오리엔트바이오 · KOSPI: 002630 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
(주)오리엔트바이오
Market / ticker
KOSPI · 002630
Industry
Pharmaceuticals and medicinal chemicals
Established
1959-04-16
Fiscal year ends
March
Website
www.orientbio.co.kr/
DART corp code
00141626
Latest revenue
₩29.4B (FY2025)

Items worth checking

medium
Operating loss in both FY2024 and FY2025.
medium
Capital reduction decided — filed 2026-06-23.
medium
Reverse stock split decided — filed 2026-03-31.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩28.8B₩28.0B₩29.4B
Operating income₩1.5B−₩646M−₩3.1B
Net income−₩12.4B₩12.9B−₩13.2B
Total assets₩81.1B₩97.0B₩84.8B
Total liabilities₩9.7B₩11.9B₩12.9B
Total equity₩71.4B₩85.1B₩71.8B
Share capital₩59.3B₩59.3B₩59.3B

Separate statements · FY2025 operating margin -10.5% · liabilities to equity 18% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 68 (current)성현회계법인Unqualified
Term 67 (prior)성현회계법인Unqualified
Term 66 (two years prior)회계법인리안Unqualified

Largest shareholder history

DateLargest shareholder (Korean)StakeCause (Korean)
2019년 02월 07일㈜오리엔트주주배정 유상증자 참여

Recent filings

DateFilingOriginal
2026-09-04Large shareholding (5%+) reportDART
2026-09-04Officer / major shareholder ownership reportDART
2026-08-14Quarterly report (2026.06)DART
2026-08-03Extraordinary shareholders meeting resultsDART
2026-07-23Large shareholding (5%+) reportDART
2026-07-16Notice of shareholders meetingDART
2026-07-08Large shareholding (5%+) reportDART
2026-06-29Independent director appointment / dismissal / resignationDART
2026-06-29Annual general meeting resultsDART
2026-06-24Amended: Officer / major shareholder trading plan reportDART
2026-06-23Officer / major shareholder trading plan reportDART
2026-06-23Record date / shareholder register closure setDART
2026-06-23Resolution to convene shareholders meetingDART
2026-06-23Material event report — Capital reduction decisionDART
2026-06-23Trading suspension and releaseDART
2026-06-19Amended: Revenue or profit structure changed materiallyDART
2026-06-19Amended: Annual report (2026.03)DART
2026-06-19Annual report (2026.03)DART
2026-06-19Audit report submittedDART
2026-06-12Officer / major shareholder ownership reportDART

Showing the 20 most recent of 40 filings. The full brief lists all of them.

Full brief on ORIENTBIO Inc. — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.